Free Trial

NIOX Group (NIOX) Competitors

NIOX Group logo
GBX 58.77 -0.23 (-0.38%)
As of 04/17/2025 12:10 PM Eastern

NIOX vs. SN, MXCT, EKF, IUG, CREO, NCYT, POLX, IHC, AVO, and RUA

Should you be buying NIOX Group stock or one of its competitors? The main competitors of NIOX Group include Smith & Nephew (SN), MaxCyte (MXCT), EKF Diagnostics (EKF), Intelligent Ultrasound Group (IUG), Creo Medical Group (CREO), Novacyt (NCYT), Polarean Imaging (POLX), Inspiration Healthcare Group (IHC), Advanced Oncotherapy (AVO), and RUA Life Sciences (RUA). These companies are all part of the "medical devices" industry.

NIOX Group vs.

Smith & Nephew (LON:SN) and NIOX Group (LON:NIOX) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, community ranking, profitability, risk, analyst recommendations, dividends and media sentiment.

Smith & Nephew received 557 more outperform votes than NIOX Group when rated by MarketBeat users. However, 100.00% of users gave NIOX Group an outperform vote while only 62.02% of users gave Smith & Nephew an outperform vote.

CompanyUnderperformOutperform
Smith & NephewOutperform Votes
560
62.02%
Underperform Votes
343
37.98%
NIOX GroupOutperform Votes
3
100.00%
Underperform Votes
No Votes

NIOX Group has lower revenue, but higher earnings than Smith & Nephew. Smith & Nephew is trading at a lower price-to-earnings ratio than NIOX Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Smith & Nephew£7.08B1.52£382.79M£27.7735.41
NIOX Group£3.53B6.84£995.88M£0.022,425.50

62.2% of Smith & Nephew shares are owned by institutional investors. Comparatively, 35.2% of NIOX Group shares are owned by institutional investors. 0.2% of Smith & Nephew shares are owned by company insiders. Comparatively, 46.7% of NIOX Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

NIOX Group has a net margin of 28.21% compared to Smith & Nephew's net margin of 5.41%. NIOX Group's return on equity of 13.29% beat Smith & Nephew's return on equity.

Company Net Margins Return on Equity Return on Assets
Smith & Nephew5.41% 5.85% 4.51%
NIOX Group 28.21%13.29%3.95%

Smith & Nephew pays an annual dividend of GBX 29 per share and has a dividend yield of 2.9%. NIOX Group pays an annual dividend of GBX 1 per share and has a dividend yield of 1.7%. Smith & Nephew pays out 104.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. NIOX Group pays out 4,126.8% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Smith & Nephew is clearly the better dividend stock, given its higher yield and lower payout ratio.

Smith & Nephew has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500. Comparatively, NIOX Group has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500.

Smith & Nephew currently has a consensus price target of GBX 4,607.50, indicating a potential upside of 368.43%. NIOX Group has a consensus price target of GBX 90, indicating a potential upside of 53.13%. Given Smith & Nephew's higher probable upside, research analysts clearly believe Smith & Nephew is more favorable than NIOX Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Smith & Nephew
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00
NIOX Group
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, NIOX Group had 8 more articles in the media than Smith & Nephew. MarketBeat recorded 8 mentions for NIOX Group and 0 mentions for Smith & Nephew. NIOX Group's average media sentiment score of 0.02 beat Smith & Nephew's score of 0.00 indicating that NIOX Group is being referred to more favorably in the news media.

Company Overall Sentiment
Smith & Nephew Neutral
NIOX Group Neutral

Summary

NIOX Group beats Smith & Nephew on 10 of the 19 factors compared between the two stocks.

Get NIOX Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for NIOX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

NIOX vs. The Competition

MetricNIOX GroupMedical Devices IndustryMedical SectorLON Exchange
Market Cap£24.14B£3.03B£5.30B£2.48B
Dividend Yield1.66%2.45%5.12%4.96%
P/E Ratio2,425.5063.5921.80129.75
Price / Sales6.84113.75379.96232,042.22
Price / Cash11.2115.9938.2628.05
Price / Book3.263.646.444.43
Net Income£995.88M£126.02M£3.21B£5.83B
7 Day Performance5.14%1.60%2.87%3.01%
1 Month Performance-3.96%-7.62%-8.63%-1.07%
1 Year Performance-9.02%-14.51%11.46%102.60%

NIOX Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NIOX
NIOX Group
2.481 of 5 stars
GBX 58.77
-0.4%
GBX 90
+53.1%
-9.6%£24.14B£3.53B2,425.5092Analyst Forecast
Gap Up
SN
Smith & Nephew
3.3048 of 5 stars
GBX 993.20
+0.0%
GBX 4,607.50
+363.9%
+2.4%£10.89B£7.08B35.7618,452High Trading Volume
MXCT
MaxCyte
N/AGBX 191
-1.0%
N/A-38.7%£252.13M£57.52M-7.0080News Coverage
Gap Down
High Trading Volume
EKF
EKF Diagnostics
N/AGBX 21.30
+0.5%
N/A-21.1%£94.67M£49.91M19.82356
IUG
Intelligent Ultrasound Group
N/AN/AN/AN/A£42.76M£6.57M-18.9165
CREO
Creo Medical Group
N/AGBX 9.72
-1.3%
N/A-71.9%£39.30M£33.87M-1.54279
NCYT
Novacyt
N/AGBX 41.79
-1.9%
N/A-32.8%£28.87M£18.12M-0.77120
POLX
Polarean Imaging
N/AGBX 1.03
-4.2%
N/A-73.8%£15.04M£5.21M-0.2628Gap Down
IHC
Inspiration Healthcare Group
N/AGBX 16.65
-0.6%
N/A-42.6%£14.42M£42.87M-1.14224
AVO
Advanced Oncotherapy
N/AN/AN/AN/A£9.50MN/A-25.003,900Gap Down
RUA
RUA Life Sciences
N/AGBX 11.45
+1.7%
N/A+3.0%£7.10M£4.05M-2.6748

Related Companies and Tools


This page (LON:NIOX) was last updated on 4/18/2025 by MarketBeat.com Staff
From Our Partners